We report the synthesis and evaluation of lecithin-gold hybrid nanocarriers for the oral delivery of drugs with improved pharmacokinetics, Au-drug interactive bioactivity and controlled drug releasing behavior at physiological pH inside human body.
We recently hypothesized that, incorporated into a surfactant, a drug-interactive motif at an interfacial region will provide an additional carrier/drug interaction mechanism, which could enhance both drug-loading capacity and formulation stability.
Both drug loading capacity and formulation stability were significantly improved by inclusion of a drug-interactive Fmoc motif.
Our improved dual function carrier with a built-in drug-interactive motif represents a simple and effective system for targeted delivery of anticancer agents.
Here we report that incorporation of a drug-interactive motif (Fmoc) into PEG5k FTS2 led to further improvement in both drug loading capacity and formulation stability.
We have developed in this study a simple and well characterized nanomicellar system that consists of an FTS-based hydrophobic domain, a PEG hydrophilic segment, and a drug-interactive Fmoc motif.
Among several motifs screened, 9-fluorenylmethoxycarbony (Fmoc) moiety, a functional group that is routinely used for amino acid protection, was demonstrated to be the most potent drug-interactive group.
We report in this study the development and characterization of a new micellar carrier composed of an FTS-based hydrophobic domain, a PEG hydrophilic segment and an interfacial drug-interactive Fmoc motif (PEG5k Fmoc FTS2).
Note that the outcome of (10) might be trivial; that is, (12) ∏ c (d → C j ) = 0 for j = 1,2, …, 100 implying that no meaningful or direct interactive drug compounds whatsoever can be found in the training dataset S′ for the drug d.
We developed a novel interactive drug discovery methodology known as Protein Chip technology (ProteoChip) as a cutting-edge PPI assay system applicable for unique PPI-targeting therapeutics integrated with computer-aided drug design (CADD).
As elaborated previously, interactive drugs always share similar side effects.
